We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma (SUMMIT-1)

This study has been terminated.
(More possibly-related deaths on tasisulam arm; failed to pass futility hurdle)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01006252
First Posted: November 2, 2009
Last Update Posted: August 15, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Eli Lilly and Company
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: August 9, 2011